Generic Ulesfia Availability

Ulesfia is a brand name of benzyl alcohol topical, approved by the FDA in the following formulation(s):

ULESFIA (benzyl alcohol - lotion;topical)

  • Manufacturer: SHIONOGI INC
    Approval date: April 9, 2009
    Strength(s): 5% [RLD]

Has a generic version of Ulesfia been approved?

No. There is currently no therapeutically equivalent version of Ulesfia available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ulesfia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods and compositions for topical treatment of ectoparasites
    Patent 5,858,383
    Issued: January 12, 1999
    Inventor(s): Precopio; Michael J.
    Assignee(s): Summers Laboratories, Inc.
    Methods and compositions for the topical treatment of ectoparasites on animal skin utilizing a water-soluble or water-dispersible, substantially air-impermeable liquid composition.
    Patent expiration dates:
    • August 11, 2017
      ✓ 
      Patent use: TOPICAL TREATMENT OF LICE INFESTATIONS
  • Methods and compositions for topical treatment of ectoparasites
    Patent 6,139,859
    Issued: October 31, 2000
    Inventor(s): Precopio; Michael J
    Assignee(s): Summers Laboratories, Inc.
    Methods and compositions for the topical treatment of ectoparasites on animal skin utilizing a water-soluble or water-dispersible, substantially air-impermeable liquid composition.
    Patent expiration dates:
    • August 11, 2017
      ✓ 
      Patent use: TOPICAL TREATMENT OF LICE INFESTATIONS
  • Ectoparasite asphyxiator compositions and methods for their applications
    Patent 6,793,931
    Issued: September 21, 2004
    Inventor(s): Michael J; Precopio
    Assignee(s): Summers Laboratories, Inc.
    Water-soluble or water-dispersible, substantially air-impermeable, pharmacologically acceptable, liquid barrier compositions for treating ectoparasite infestations on animal skin and hair, wherein the compositions contain at least one monohydric aralkyl alcohol to prevent the ectoparasites from closing their respiratory systems.
    Patent expiration dates:
    • July 11, 2022
      ✓ 
      Patent use: TOPICAL TREATMENT OF LICE INFESTATIONS
      ✓ 
      Drug product
  • Ectoparasite asphyxiator compositions and methods for their application
    Patent 7,294,342
    Issued: November 13, 2007
    Inventor(s): Precopio; Michael J
    Assignee(s): Summers Laboratories, Inc.
    Water-soluble or water-dispersible, substantially air-impermeable, pharmacologically acceptable, liquid barrier compositions for treating ectoparasite infestations on animal skin and hair, wherein the compositions contain at least one monohydric aralkyl alcohol to prevent the ectoparasites from closing their respiratory systems, and wherein the compositions are free from pesticides.
    Patent expiration dates:
    • May 19, 2024
      ✓ 
      Patent use: TOPICAL TREATMENT OF LICE INFESTATIONS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 9, 2014 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)